Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): Objective and protocol

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 2, 1997, Pages 188-192

  Wing, L M H ^a   Reid, C M ^a,b   Beilin, L J ^a   Brown, M A ^a   Jennings, G L R ^a   Johnston, C I ^a   McNeil, J J ^a   Marley, J E ^a   Morgan, T O ^a   Ryan, P ^a   Shaw, J ^a   Steven, I D ^a   West, M J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b HBPRCA   (Australia)

Author keywords

ANBP2 outcome trial; Angiotensin converting enzyme inhibitor; Diuretics; Hypertension

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 8244248798     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb01806.x     Document Type: Article

References (23)

1. Collins R, Peto R, McMahon S et al. Blood pressure, stroke and coronary artery disease. Part II: Effects of short-term reductions in blood pressure. An overview of the unconfounded randomised drug trials in an epidemiological context. Lancet 1990; 335: 827-38.
2. McMahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary artery disease. Part 1: Effects of prolonged differences in blood pressure. Evidence from nine prospective observational studies corrected for regression dilution bias. Lancet 1990; 335: 765-74.
3. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.
4. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ 1992; 304: 405-12.
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991; 265: 3255-64.
6. Veterans Administration Co-operative Study Group on Antihypertensive Agents. Effects of treatment on morbidity of hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213: 1143-52.
7. Australian National Blood Pressure Study Management Committee. The Australian therapeutic trial in mild hypertension. Lancet 1980; i: 1261-7.
8. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. BMJ 1985; 291: 97-104.
9. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC V). Arch. Intern. Med. 1993; 153: 154-83.
10. Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: Memorandum from a World Health Organisation/International Society of Hypertension meeting. J. Hypertens. 1993; 11: 905-18.
11. Sever P, Beevers G, Bulpitt C et al. Management guidelines in essential hypertension: Report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983-7.
12. The management of hypertension: A consensus statement. Med. J. Aust. 1994; 160 (Suppl.): S1-16.
13. Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins. J. Hypertens. 1985; 3: 297-306.
14. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Engl. J. Med. 1989; 321: 868-73.
15. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am. J. Hypertens. 1992; 5: 95-110.
16. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 1987; 316: 1429-35.
17. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991; 325: 293-302.
18. Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N. Engl. J. Med. 1992; 327: 669-77.
19. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 1992; 327:685-91.
20. Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297: 1092-5.
21. Mathiesen ER, Hommel E, Giese J, Parving H-H. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303: 81-7.
22. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993; 329: 1456-62.
23. Hansson L, Hedner T, Dahlöf B. Prospective Randomised Open Blinded Endpoint (PROBE) Study. A novel design for intervention trials. Blood Pressure 1992; 1: 113-19.